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ABSTRACT 
    
Contamination of powdered infant formulas by the bacteria Cronobacter sakazakii can 
pose serious risk to infants and neonates who consume the formula and subsequently develop C. 
sakazakii related illnesses such as sepsis and meningitis (1).  
The Gibbs’ lab assesses C. sakazakii isolates’ ability to cross the blood brain barrier and 
cause meningitis. This thesis research investigated C. sakazakkii cytotoxicity towards 
microvascular endothelial cells which comprise the first cell line encountered in the barrier. 
Understanding the mechanisms used to affect these cells will contribute to our understanding of 
early stages of invasion. 
Cytotoxicity assays performed for this research found that the cell line used could not 
sustain confluency when co-cultured with C. sakazakii isolates over periods beyond 24 hours of 
incubation. In addition, cell-free cytotoxicity assays found that live cells are not necessary to 
cause damage suggesting a toxin mediated effect. 
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LITERATURE REVIEW 
Research Note & History of the Cronobacter Genus 
 The research done for this thesis focuses on the species Cronobacter sakazakii. This 
species is not synonymous with Enterobacter sakazakii. The old E. sakazakii designation refers 
to what is today recognized as multiple Cronobacter species including C. sakazakii and nine 
others. Much of the early research pertaining to general characteristics of Cronobacter was done 
under the E. sakazakii designation and is therefore still pertinent to this study. Any literature 
prior to 2007 referring to E. sakazakii will be noted as: Cronobacter Complex throughout the 
thesis to make a clear distinction between references to multiple and single species. 
 
 
 
Figure 1: Cronobacter Genus Naming History 
 The Cronobacter genus has a complex history that began in 1980 and continues today as 
advances in technology have made clear classification within the genus possible (2–7). Initially, 
species of the Cronobacter genus were not recognized distinctly from other species within the 
Enterobacteriaceae family and were classified with various names such as “yellow pigmented 
Enterobacter cloaceae” (3). The first reclassification began with multiple members of the 
Cronobacter  genus being grouped together as one species in the Enterobacter genus as E. 
sakazakii (3, 4). As more sophisticated genetic analysis became available, the E. sakazakii 
Various 
Classifications within 
Enterobacteriacea 
Classification of multiple 
members as Enterobacter 
sakazakii species 
Classification as  
Cronobacter genus 
with distinct species 
Cronobacter Genus 
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species was recognized as several distinct species and the Cronobacter genus was created (4). 
New species continue to be classified into the genus as taxonomic resolutions and discoveries 
continue to be made (6, 7).  
Classification into Enterobacter sakazakii Species 
Prior to 1980, members of the Cronobacter genus were classified under various names 
including: “yellow pigmented E. cloaceae”, “yellow coliform”, Serratia sp., and 
Chromobacterium (3). In 1980 Farmer et al. proposed that the organism formerly classified as 
“yellow pigmented Enterobacter cloacae” be separated into a separate species,“E. sakazakii,”; 
this was done based on DNA-DNA hybridization experiments which showed that the organism 
met criteria to form its own species (3).  
Classification of the Cronobacter Genus  
 In 2007, further taxonomic studies provided data to support placing E. sakazakii into a 
novel genus, Cronobacter, and to separate the genus into five species and one genomospecies: C. 
sakazakii, C. malonaticus, C. turicensis, C. muytjensii, C. dublinensis, and C. genomospecies 
1(4). The genomospecies was later classified in 2011 as C. universalis and at this time C. 
condiment was shown to be a novel species as well (7). As of the fall of 2013, an additional 3 
species (C. zurichensis, C. helveticus, and C. pulveris) were identified and added to the 
Cronobacter genus bringing the total number of species up to 10 (6, 8). These three species were 
originally classified between 2007-2008 as Enterobacter species, but were recently re-classified 
into the Cronobacter genus with their original species designations (except for E. turicensis) 
after further genetic analysis(6, 9, 10). 
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Etymology of the Cronobacter Genus Nomenclature 
 The original designation of E. sakazakii was proposed in honor of Riichi Sakazakii, a 
Japanese microbiologis, veterinarian, and taxonomist who contributed substantially to the study 
of Enterobacteriaceae and named several species in the genus (3, 11). 
 When research warranted the addition of a novel genus for Enterobacter sakazakii, 
Cronobacter was chosen to represent the Greek Titan Cronus who consumed his children at birth 
to prevent them from overthrowing his rule(12, 13). Cronus was chosen due to the notoriety of 
the species C. sakazakii and its ability to cause rare but often fatal cases of neonatal meningitis 
which causes swelling of the tissues surrounding the infant brain (4, 14).  
 The first five species identified in the genus were named according to their original 
country of discovery, after notable researchers, or due to their unique biochemical properties or 
(4). The first species contained the largest number of isolates and was named C. sakazakii to 
continue to honor the work of Riichi Sakazakii; the type strain for this organism remains ATCC 
29544 which was originally obtained from a throat culture taken from a patient in Tennessee in 
1970 and designated by the CDC as 4562-70 (3, 4). C. malonaticus was originally proposed as a 
subspecies of C. sakazakii but later was shown to be a closely related but distinct species; it was 
named for the use of malonate which varies within the genus (4, 15). C. muytjensii was named to 
honor another microbiologist, Henry Muytens, who contributed to the initial studies of 
Enterobacter sakazki; the type strain for this species is ATCC 51329 (4). Both C. dublinensis 
and C. turicensis were named for the cities that the proposed type strains originated from: 
Dublin, Ireland and Zurich, Switzerland respectively(4).  
4 
 
 The five speices that were added to the Cronobacter genus after 2007 were named as 
follows. C. condiment was isolated from a spiced meat product and references the origin of the 
organism in condiments; C. unversalis was proposed as a distinct species designation for strains 
previously designated in the genomospecies 1 group (7). Both C. zurichensis and C. helveticus 
were named for their origins in Zurich and Helvetica Switzerland; E. turcensis was renamed as 
C. zurichensis as the name was already used in the Cronobacter genus to designate another 
distinct species(6). E. pulvaris was reclassified as Cronobacter under the same species name 
which originated from its discovery as a contaminant in powdered products (6, 9).  
General Characteristics of Cronobacter Complex and C. sakazakii 
 The Cronobacter genus belongs to the class Gammaproteeobacteria and the family 
Enterobacteriaceae (7). It contains Gram negative rods that measure 3 microns by 1 micron, and 
are facultative anaerobes that are generally motile by peritrichous flagella; they do not form 
spores (3, 4). One gene contained in all sequenced members of this family is the crtZ gene which 
codes for the characteristic yellow pigment; however not all Cronobacter species express the 
gene (5, 16). Characteristic biochemical test results are extensively described by both Farmer et 
al and Iverson et al (3, 4). Studies have reported that members of this genus can grow at 
temperature ranges between 6 
o
C and 47 
o
C, with an optimal growing range between 37 
o
C and 
43 
o
C (2, 17, 18). At an optimal growing temperature of 37 
o
C,  Cronobacter Complex double on 
average every 22 minutes (17). The growth characteristics of the species is dependent upon 
growth conditions, environmental stress, and media used; studies have shown that these bacteria 
do not grow the same in food products as they do in laboratory simulated conditions meant to 
mimic them (19–21). 
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 C. sakazakii and Cronobacter Complex can be found ubiquitously in the environment on 
various locations including: solid and liquid food products, households, factory settings, and 
even within insects such as flies (22–25). Plants have been suggested as the natural reservoir for 
the organism (26). A review of literature pertaining to globally contaminated food products 
showed Cronobacter Complex can be found on cereal products, legumes, tea/spices, fruits, 
vegetables, dairy products, meat products and even in water sources (22). Notably, Cronobacter 
Complex has been found to contaminate powdered infant formula (PIF) in 13 different countries, 
including: Australia, Canada, France, Germany, India, and the US (24). Contaminated PIF has 
been associated with serious neonatal diseases which will be discussed under ‘Clinical 
Significance’ (27–32).  
 The survival traits associated with C. sakazakii and Cronobacter Complex have been 
attributed to the organism’s ability to persist in such varied environmental locations, including 
food products (19, 18, 33, 17, 34). Of note is the organism(s)’ ability to survive drying, osmotic, 
and heat stress (18, 33, 34). Studies of Cronobacter Complex have shown that some isolates can 
survive for up to 2.5 years in dehydrated powdered infant formula which can be an important 
food contamination vehicle and that in general, these organisms can survive drying better than 
other members in the Enterobacteriaceae family such as E. coli (18, 33). The ability of this 
group to survive heat stress was initially debated as studies showed conflicting results with 
respect to thermal tolerance (18, 34).  Later studies showed that heat tolerance is dependent on 
the strain of Cronobacter Complex and the growth conditions used (20).  Certain isolates have 
been shown to survive temperatures as high as 58-60 
o
C with stationary cells at near-neutral pH 
(20, 21, 34). Nine thermotolerant strains of C. sakazakii surviving for 102- 217 s at 58 C have 
been reported and were found to share the same DNA marker for heat resistance,. orfI (35, 36). 
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Heat stress has also been shown to affect the antibiotic resistance of C. sakazakii which results in 
increased resistance to a number of antibiotics including gentamicin and ampicillin which are 
used for treatment in C. sakazakii associated meningitis (19). 
Antimicrobial Susceptibility Characteristics 
 Cronobacter Complex was initially reported by Farmer et al to be sensitive to the protein 
synthesis inhibiting antibiotics gentamicin, kanamycin, and the cell wall inhibiting antibiotics 
ampicillin and chloramphenicol (3). Clinical reviews agree with these findings and report that in 
addition, these bacteria are also sensitive to  penicillin and third generation cephalosporins and 
the antimetabolite trimethroprim sulfamethazide although at least five cases have shown 
resistance to ampicillin (32). Cronobacter Complex show resistance to beta-lactams (32, 37). 
 In a study of different strains of C. sakazakii, unstressed bacteria were sensitive to: the 
protein inhibiting aminoglycosides streptomycin, gentamicin, and kanamycin; the cell wall 
disrupting penicillin amoxicillin;and to the nucleic acid disrupting flouroquinolone ciprofloxacin 
(19). These same strains were resistant to the aminoglycoside neomycine, to two protein 
inhibiting tetracyclines-tetracycline and doxycycline- and the cell wall synthesis inhibiting 
antibacterial drug vancomycin (19). 
Clinical Significance 
 Cronobacter Complex and Cronobacter sakazakii are able to cause disease across age 
groups, but have the most severe impact on the immune-compromised portion of the population 
including neonates and the elderly (1, 32). Due to the re-classification of Cronobacter Complexin 
1980 and C. sakazakii  in 2007, it is at times difficult to track historical cases of disease and to 
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distinguish which species is the causative agent of disease without retrospective investigation (2, 
28). 
 Diseases associated with Cronobacter Complex include: bacteremia, conjunctivitis, 
dermoid cysts, diarrhea, neonatal meningitis, necrotizing enterocolitis (NEC), sepsis, urinary 
tract infections, and wound infections (1, 27–32, 38). These diseases most often affect infants 
and neonates (1, 27–32, 38).  
The current surveillance systems in place do not actively monitor infections caused by C. 
sakazakii or other Cronobacter species although Minnesota enacted mandatory passive 
surveillance for invasive infection in children in 2005 (1, 28). Therefore, due to lack of active 
reporting and small existing data sets, the incidence and disease prevalence caused by 
Cronobacter sakazakii and other Cronobacter species have not been established (28).   
In a global call for data, the Food and Agricultural Organization of the United Nations 
(FAO) and World Health Organization (WHO) found that reported infections caused by 
Cronobacter species in neonates and infants often progress to NEC, meningitis, and bacteremia 
(28). The mechanism of pathogenesis leading to these diseases remains unknown although 
researches have begun to elucidate several virulence related characteristics and genes (39–41).  
Meningitis Symptoms, Treatment, and Outcomes in Infants 
 Meningitis is characterized by an inflammation of the membranes that surround and 
protect the brain (14). The Centers for Disease Control and Prevention describe the symptoms of 
infant and neonatal meningitis as nonspecific and may “include [. . . fever], poor feeding, and 
listnessness (1).” The CDC reports that diagnosis is usually made through laboratory testing and 
culture of blood and or cerebrospinal fluid followed by appropriate identification steps (42). The 
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outcomes of Cronobacter Complex associated meningitis can range from complete recovery to 
severe complications such as quadriplegia, brain cysts, developmental delays, mental retardation, 
and death (28, 30, 32, 38). 
Cronobacter species that have been associated with meningitis are : C. sakazakii, C. 
malonaticus, and C. turicensis (4). Current treatment for meningitis associated with these species 
includes the use of third generation cephalosporin in conjunction with gentamicin and ampicillin 
(32). Meningitis-related fatality rates associated with Cronobacter species vary by individual 
outbreak; however, of the known cases reviewed by the FAO and WHO the overall fatality rate 
is 40% with some survivors experiencing severely impaired brain function (27, 28, 32). 
Pathogenesis 
 Virulence traits and pathogenic mechanisms associated with C. sakazakii and other 
species within the genus remains largely unknown, although initial studies have begun the 
process of identifying specific genes, properties, and pathways involved in the infection process. 
 Initial research on C. sakazakii and Cronobacter Complex has revealed that these species 
are able to form biofilms, possess iron acquisition genes, and are able to persist in human 
macrophages (8, 16, 37, 43–45).  Cronobacter Complexalso possess zinc metalloproteases which 
can target host cells (16, 46). One C. sakazakii plasmid, pESA3, codes for a plasminogen 
activator and Type Six Secretion System (highly variant) which are associated with resistance to 
complement activity and molecular delivery respectively (41, 44). The endotoxin of Cronobacter 
Complex has been shown to increase the bacterial ability to translocate cells in rat intestines, 
although other secreted factors are suspected to aid in translocation (47). Such factors could be 
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delivered through an intact Type Six Secretion System which some Cronobacter  Complex 
species possess (16). 
 Tissue culture studies have shown that specific isolates of C. sakazakii and Cronobacter 
Complex are able to adhere to and invade a number of cell lines including the following human 
cell types: Caco-2 intestinal epithelial cells, INT 407 intestinal epithelial cells, brain 
microvascular endothelial cells, brain capillary endothelial cells and can survive within 
macrophages (39, 40, 45, 48–50). Adherence occurs in either aggregate or diffuse patterns and 
invasion rates of specific cell lines vary between isolates ranging from high to low (39, 51). 
Disruption of host cell tight junctions has been shown to increase invasion rates of the above 
mentioned intestinal epithelial cell lines and is suspected to increase invasion in endothelial cells 
as well (40, 45).Outer membrane proteins OmpA and OmpX are required for invasion of Caco-2 
and INT 407 cell lines while invasion of brain microvascular endothelial cells requires 
cytoskeleton rearrangement through the utilization of host P13K/Akt signaling pathway (40, 49, 
50).  
Blood Brain Barrier  
 The blood brain barrier (BBB) is composed of three major cell that are responsible for 
forming a selectively permeable barrier which ensures the brain maintains homeostasis (52–54). 
These cell types include brain microvascular endothelial cells (BMEC), glial cells called 
astrocytes, and pericytes which are related to smooth muscle cells (14, 52–54). Together, the 
astrocytes and pericytes help maintain barrier properties while providing structural support (52, 
53). 
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 The tight junctions between BMECs of the blood brain barrier differ from junctions 
elsewhere in terms of their complexity and tightness between cells (52, 55). BBB tight junctions 
are 50-100x tighter than other junctional complexes and provide high electrical resistance that 
helps restrict paracellular movement and prevent the free diffusion of harmful solutes (52, 55). 
The lipid membranes of the BBB cells allow free movement of oxygen, carbon dioxide, ethanol 
and fat soluble molecules through the plasma while other essential nutrients must use carrier 
systems to cross the barrier; harmful substances and non-essential nutrients cannot access the 
barrier and are actively removed (14, 52). 
C. sakazakii Traversal of BBB 
Pathogenic invasion of the blood brain barrier is incompletely understood and most likely 
involves complex host-pathogen interactions (56, 57). Disease progression from C. sakazakii 
infection in neonates has been linked with contaminated powdered infant formula and is 
proposed to progress from NEC cases. In a review of bacterial meningitis, the progression is 
proposed to occur as follows: invasion of and escape from the gut followed by survival in the 
blood until contact and invasion of the blood brain barrier is achieved (58). In C. sakazakii, 
meningitis could develop after NEC infection by the same route. After ingestion of contaminated 
PIF, the bacteria must colonize the gut epithelium. To cause initial infection; the bacteria must 
also invade these cells and develop into necrotizing enterocolitis, then bacteremia (59). As 
previously stated, Cronobacter complex has been shown to be able to invade intestinal epithelial 
cells in vitro (39, 48). Once in the blood, C. sakazakii must maintain high numbers and travel to 
sites of the blood brain barrier where it must finally cross the barrier to cause meningitis (60). 
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Survival in the blood may be possible in part due to Cronobacter plasminogen activator which 
confers resistance to components of the innate immunes system such as C3, C3a, and C4b (41). 
Bacterial traversal of the blood brain barrier is proposed to occur via three possible 
mechanisms: paracellular, transcellular, or  by phagocytic transport (54, 60). Among meningitis 
causing pathogens, more than one method of traversal may be utilized by the same organism (53, 
54). Two possible mechanisms appear possible for C. sakazakii: transcellular and phagocytic 
transport. Studies have shown that C. sakazakii can survive within macrophages which are able 
to cross the BBB (45). In addition, one type of neuroglia cell of the BBB, microglial cells, can 
differentiate into macrophages when bacteria are present (14). Phagocytized bacteria could 
survive traversal within either circulating or differentiated macrophages. Transcellular traversal 
investigation has shown that C. sakazakii is able to invade brain microvascular endothelial cells 
and to cause cytoskeletal rearrangements via P13K/Akt signal transduction (39, 45, 49, 50).  
Research Experiments and Rationale 
Our research with C. sakazakii aims to enhance both our understanding of the 
transcellular mode of traversal as well as bacterial BBB traversal as a whole. C. sakazakii 
isolates from clinical cases and fecal sources were studied to detect the cytotoxic effects of the 
species on mouse endothelial cells and to assess the suitability of the endothelial cell line for use 
in an astrocyte-endothelial co-culture system which is currently under development in Dr. Gibbs 
lab. The use of such a system will contribute to our overall understanding of bacterial interaction 
with the BBB as various pathogens could be inoculated into the system and observed.  
Isolates were first characterized with respect to growth, antibiotic susceptibility, and 
motility to compare individual isolate characteristics to existing literature.  The isolates used 
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show growth and antibiotic susceptibility patterns that are similar to those described previously 
(17, 61). 
Next, isolates were cultured with endothelial cells to assess cytotoxicity over long-term 
incubation periods both with whole cell samples and cell-free supernatant. All whole-cell isolates 
damage the endothelial cells after 24 hours, causing cell rounding and death. The most cytotoxic 
isolate, BAA 894 was chosen for further study with cell-free supernatant. This isolate caused 
similar damage to EOMA cells as the whole-cell sample, although damage occurred earlier. 
These findings show that live bacteria are not required for cell damage and that the effects seen 
may be a result of a combination of contact and toxin mediated damage. 
 Invasion and adhesion assays were also performed to assess whether the C. sakazakii  
isolates are able to invade the mouse endothelial cells similar to invasion seen in human 
endothelial cell lines. This would ensure that the use of the mouse system closely mimics true 
pathology in human cells. The invasion and adhesion assays were not completed due to time 
spent re-calibrating the protocol for use with the particular cells. Future use of an updated 
protocol will give conclusive results.  
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MATERIALS AND METHODS 
Bacterial Isolates 
            Both prokaryotic and eukaryotic cells were used for experimentation. Cell isolates were 
used for bacterial and co-culture experiments; a complete list of isolate origin and designation 
can be found below in Table 1.  
Table 1: Isolates Used For Experimentation 
Domain  Genus Species Cell Type Origin Designation 
Eukaryote Mus musculus Endothelial Derived from mouse 
hemangioendo-
thelioma 
ATTC CRL-2586 
EOMA 
Prokaryote Cronobacter sakazakii Bacteria Clinical Isolate from 
bison feces 
52 
Prokaryote Cronobacter sakazakii Bacteria Isolated from 
powdered infant 
formula  
ATTC BAA-894 
BAA-894 
Prokaryote Cronobacter sakazakii Bacteria Clinical isolate from 
cerebral spinal fluid 
of infant 
CT2 
Prokaryote Cronobacter sakazakii Bacteria Clinical isolate from 
bovine feces 
N72 1A 
Prokaryote Escherichia coli Bacteria ATTC 11775 K1 
Prokaryote Escherichia coli Bacteria DH5α DH5 α 
Prokaryote Salmonella enterica Bacteria ATTC BAA-664 
(Braenderup) 
BAA-664 
 
Growth Conditions 
Bacterial Isolates 
 All bacterial isolates were maintained as freezer stock in 900 µl LB with 600 µl of 50% 
glycerol at -80 C. For experimental use of desired freezer stock, an isolation streak onto Luria 
Bertani (LB) agar plates was performed. LB plates were incubated at 37
o
C overnight. 
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 For the Antibiotic Disc Diffusion Assay, isolated bacterial colonies were picked and 
transferred to 3 ml LB broth and allowed to grow to an OD600 ≈ 0.2-0.25 and plated on Mueller-
Hinton Agar. For Cytoxicity Assays, bacterial isolates were plated onto MacConkey Agar 
(MAC) plates for differentiation . For Supernatant and Gentamicin/Adhesion Assays, a single 
colony of each desired bacterial isolate was picked off of each LB plate and transferred to 5 ml 
LB broth. Cultures were incubated overnight with shaking at 150 rpm. During Growth Curve 
Experiments, bacteria were incubated in 1ml LB broth at 37
o
C for up to 48 hours. For Motility 
Assays, single colonies were removed from LB plates and inoculated onto motility plates. All 
media and reagents used for the bacterial experiments are included in Table 2. 
Cell Culture  
 Endothelial cells were maintained in T-75 cell cultures flasks with Complete Dulbeco’s 
Modified Eagle’s Medium (C-DMEM) with 5% CO2 at 37
o
C. Cell culture lines were maintained 
for up to 64 passages. For long term storage, freezer stocks were maintained with 95 % C-
DMEM and 5% DMSO in liquid nitrogen. 
 For Cytotoxicity and Supernatant assays, endothelial cells were grown to confluency on 
chamber slides and stored at 5% CO2 and 37
o
C for up to 48 hours. Endothelial cells were grown 
on 6-well plates for the Gentamicin/Adhesion Assays and stored under the same conditions for 2-
24 hours. Media and reagents used for co-culture experiments are described in Table 2. 
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Media and Reagents  
Table 2: Media and Reagents 
Name Abbreviation Composition 
1 X Phosphate Buffered 
Saline (Cell Culture 
Grade) 
1X PBS Not Available 
Amikacin** AN--30 30 ug disc potency 
Amoxicillin/Clavulanic 
Acid** 
Amc-30 20/10 ug disc potency 
Ampicillin** AM- 10 10 ug disc potency 
Ceftiofur** XNL-30 30 ug disc potency 
Cephalothin CF-30 30 ug disc potency 
Chloramphenicol** C-30 30 ug disc potency 
Diff-Quick Stain Kit Diff-Quick Sln 1: 3.7% Formaldehyde,90% Methanol 
 
Diff-Quick Stain Kit Diff-Quick Sln 2: .1%Azure II,.1% Phenothiazin-5-ium, 3,7-
bia(dimethylamino)-chloride, 1% sodium phosphate monobasic 
monohydrate, 1%sodium phosphate, dibasic, anhydrous 
Diff-Quick Stain Kit Diff-Quick Sln 3: .1% Eosin Y, .7% Sodium phosphate monobasic 
monohydrate, .3% sodium phosphate, dibasic, anhydrous 
Dulbeco’s Modified 
Eagle’s Medium 
DMEM 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate, 
and 1500 mg/L sodium bicarbonate 
Fetal Bovine Serum FBS Not Available 
Gentamicin** GM 10 10 ug disc potency 
Hematoxylin  <.6% hematoxylin powder, <30% Ethylene glycol, <5% 
Aluminum sulfate, <.1% Sodium iodate, <.2% Hydrochloric acid, 
<5% Aluminum ammonium sulfate 
Kanamycin** K -30 30 ug disc potency 
Luria Bertani broth and 
agar 
LB 1% Tryptone, 0.5% Yeast Extract, 1% NaCl 
MacConkey Agar MAC 0.017% Pancreatic digest of gelatin, 0.003% Peptone, 0.01% 
Lactose,0.0015% Bile Salts #3, 0.05% NaCl, 0.0135% agar, 
0.000003% Neutral Red, .0000001% Crystal Violet 
Motility Agar*  1% Tryptone , 0.5% NaCl, 0.3% agar 
Mueller Hinton Agar  0.0175% Casein hydrolysate, 0.0015% Starch, 0.002% Beef 
Infusion Solids, 1.7% Agar 
Nalidixic Acid** Na-30 30 ug disc potency 
Streptomycin** S-10 10 ug disc potency 
Sulfisoxazole** G .25 250 ug disc potency 
Tetracycline** TE-30 30 μg disc potency 
Tousimis Glutaraldehyde  2.5% in .1 M Na/K Sorensen’s Phosphate buffer 
Trypsin-EDTA  0.05% Trypsin and 0.02% EDTA 
Lyse Solution***  2.5% Trypsin, .1% Triton-X, 80% PBS 
Gentamicin  10mg/mL 
All chemical and reagent information was found in MSDS unless otherwise noted. 
* (62) ** (63) ***(64) 
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Bacterial and Co-Culture Experiments 
Growth Curve 
 Growth curves were performed utilizing a single colony of each bacterial isolate in 3ml 
of LB. Tubes were incubated overnight at 37
o
C with shaking at 140 rpm. Overnight cultures 
were then diluted 1:100 and dispensed into 1.5 ml microfuge tubes which were stored at 37
o
C. 
OD600 readings were taken hourly from hour 0 to 8 and then at hours 12, 24, and 48 with an 
Eppendorf BioPhotometer (Hamburg, Germany). A dilution series was performed for each 
hourly sample to determine the CFU/ml. Two replicates were performed for each bacterial 
isolate. To analyze the data, the averages and standard deviations were calculated for OD600 and 
CFU/ml data, separately for each bacterial isolate and time point. The two data sets were then 
graphed on a scatterplot with OD600 readings vs time on a logarithmic scale and CFU/ml vs time 
on a linear scale. The doubling time for each isolate was determined by using CFU/ml 
corresponding to the log phase of each growth curve. The doubling time for each isolate was 
calculated using the following formula: G= t/3.3 logb/B (65). Where: G represents generation 
time, t represents time in minutes, b represents the number of bacteria at the end of the time 
interval, and B represents the number of bacteria at the beginning of the time interval. 
Antibiotic Susceptibility Testing 
 To determine the susceptibility of each bacterial isolate to 12 different antibiotics, the 
Kirby-Bauer disc diffusion method was used with 150 X 15 mm Mueller-Hinton agar plates (63). 
Prior to testing, each bacterial isolate was incubated in 3 ml of LB until an OD600 ≈ 0.2-0.25 was 
reached. Sterile swabs were then used to inoculate bacteria from the liquid cultures onto Mueller-
Hinton agar plates, spreading the bacteria across the entire surface of the plate. After inoculation, 
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antibiotic discs were dispensed onto individual agar plates. Following overnight incubation at 
37
o
C, antibiotic susceptibility was determined by measuring the zone of inhibition for each 
antibiotic and bacterial isolate. One replicate was performed for each sample. BIOMIC 2010 
software and the Kirby-Bauer XNL program were utilized for analysis. The software 
distinguished between three categories of antibiotic susceptibility: susceptible, intermediate, and 
resistant. The zones that separate these categories are characteristic for each antibiotic. The 
software compared the measured inhibition zones to these standard inhibition zones to categorize 
the isolates with respect to the different antibiotics.  
Motility 
The motility of each bacterial isolate was determined at 25
o
C and 37
o
C using 150 x 15 
mm motility plates. Single colonies were inoculated into the center of each plate and the 
diameter (in mm) of the growth rings were measured hourly until they reached the edge of the 
plate. Three replicates were performed for each bacterial isolate. To analyze the data, the 
averages and standard deviations of the diameters were calculated across the replicates for each 
bacterial isolate. The growth ring data were then plotted in mm diameter vs time in hours on a 
linear scale. The rate of movement was determined for each isolate by determining the linear 
regression of the growth ring data. Data are expressed in mm/hr. 
Chamber Slide Assays 
 All chamber slides were inoculated with EOMA cells, which were allowed to grow to 
confluency prior to experimental inoculation with bacterial isolates.  
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  Cytotoxicity Assay 
 Bacterial isolates were grown overnight in LB broth at 37
o
C 150 rpm. Each isolate was 
then diluted and 10
8 
cfu/mL were pipetted into the chamber slides with the confluent monolayer 
of EOMA cells. Co-cultures of bacterial and EOMA cells were incubated at 37
o
C and 5% CO2 
for 24, 36, & 48 hours. After incubation, the supernatant from each isolate was plated onto 
MacConkey agar and chamber slides were processed with glutaraldehyde. Cells were stained 
with hematoxylin or Diff-Quick, and viewed under an Olympus BX61 bright field microscope 
(Center Valley, PA) at 200 x, 600 x, and 1000 x magnification. Three replicates were performed 
for each bacterial isolate co-cultured with the EOMA at each time point. Representative images 
were taken for each bacterial isolate producing between 25-30 images per isolate at each time 
point.  Data were qualitatively analyzed and one representative image is shown per bacterial 
isolate (in co-culture with the EOMA cells) and time point.  
  Supernatant Assay 
 Bacterial isolates were grown in LB overnight. Supernatants were obtained by 
centrifuging the overnight cultures at 4000 rpm for 10 minutes at 25C.  The supernatant of each 
isolate was filtered through a 3 micron filter and inoculated on top of the confluent monolayer of 
EOMA cells in the chamber slides. Chamber slides were incubated at 37
o
C at 5% CO2 for 24, 36, 
& 48 hours. Live views of co-cultures were taken on  a Zeiss AxioObserver Z1, and PlasDIC set, 
equipped with with Zeiss HRc Rev3 color camera and Zeiss AxioVision Rev. 4.8.1 microscope 
control software. (Zeiss Microimaging, Thornwood NY). All images were taken at 200x. Three 
replicates were performed for each supernatant at each time point. Representative images were 
taken for each sample producing between 25-35 images per isolate at each time point. Data were 
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qualitatively analyzed and one representative image is shown per supernatant (in co-culture with 
the EOMA cells) and time point.  
Gentamicin and Adhesion Assays 
 Assays were prepared by growing a confluent monolayer of EOMA cells in 6-well plates. 
All plates were stored at 37
o
C and 5% CO2. The assay was performed as described by Berry et al, 
2009 (64). 
 Gentamicin Assay 
 Each bacterial isolate was aseptically inoculated into individual wells of the plate at a 
multiplicity of infection of 10. The plates were then centrifuged at 600x gravity for 2.5 minutes 
twice. After centrifugation to enhance bacterial and EOMA cell contact, plates were incubated at 
37
o
C for two hours. Gentamicin was then added to each well and plates were inoculated for an 
additional half hour. Following the final incubation, each well was washed with 4mL PBS and 
EOMA cells were then lysed with the lyse solution described in Table 1. A dilution series was 
performed for the contents of each well and all dilutions were plated on LB to enumerate the 
number of colony forming units of each isolate in all wells. The number of cfu/ml of each isolate 
represents the number of intracellular bacteria for each well. This number can then be compared 
to the number of total bacteria in each well (determined in the Adhesion) to calculate the percent 
invasion of EOMA cells for each isolate. 
 Adhesion Assay 
 Each bacterial isolate was aseptically inoculated into individual wells of the plate at a 
multiplicity of infection of 10. The plates were then centrifuged at 600x gravity for 2.5 minutes 
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twice. After centrifugation to enhance bacterial and EOMA cell contact, plates were incubated at 
37
o
C for two hours. Each well was washed with 4mL PBS and EOMA cells were then lysed with 
the lyse solution described in Table 1. A dilution series was performed for the contents of each 
well and all dilutions were plated on LB to enumerate the number of colony forming units of 
each isolate in all wells. The number of cfu/ml of each isolate represents total number of bacteria 
that remain attached plus the number that have invaded the EOMA cells. This number can then 
be used to calculate percent invasiveness for each isolate as described above in the Gentamicin 
Assay. 
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RESULTS 
Antibiotic Susceptibility of the Bacterial Isolates 
 In order to validate the use of the bilayer blood brain barrier system and the pathogenesis 
caused by bacteria, individual E. coli and C. sakazakii bacterial isolates listed in Table 1 were 
first characterized to ensure they represent properties as previously described. Antibiotic 
susceptibility testing, growth curves, and motility analysis were performed to gain a preliminary 
understanding of both the control and test organisms’ physical and chemical properties. 
 Antibiotic susceptibility testing was performed using the disc diffusion method and 
representative drugs from the following drug classes: aminoglycoside, cephalosporin, 
chloramphenicol, penicillin, quinolone, sulfonamide, and tetracycline. Individual 150 mm plate 
with Mueller-Hinton agar plates were aseptically inoculated with the control strains of E. coli 
and test strains of C. sakazakii using cultures standardized to an OD600 ≈ .2-25. After completely 
covering each plate with an individual strain of bacteria listed below in Table 3, twelve different 
antibiotic discs (BD BBL Sensi-Disc, Maryland) were added to each plate and grown overnight 
at 37
o 
C. Plates were then analyzed with BIOMIC 2010 software utilizing the Kirby-Bauer-XNL 
program to assess zones of inhibition. Results are shown below in Table 3.  
 The cytotoxicity and supernatant assay control strains of E. coli, DH5 α and K1, both 
showed sensitivity to all antibiotics tested, with the exception of nalidixic acid (NA-30). DH5 α 
showed an intermediate susceptibility to this nucleic acid disrupting quinolone. DH5α is a non-
pathogenic K12 strain of E. coli that is sensitive to most antibiotics; this strain is unable to 
colonize intestines and lacks most virulence factors (66, 67).The findings from this antibiotic 
screen, agree with this data. E. coli K1 strains have been shown to be sensitive to ampicillin, 
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chloramphenicol, and gentamicin (68). The K1 strain used in this study is also sensitive to these 
drugs.  
 The C. sakazakii isolates used in this study were uniformly resistant to cephalothin (CF-
30) and uniformly sensitive to all other antibiotics tested including: gentamicin (Gm-10), 
ampicillin (Am-10), chloramphenicol (C-30), kanamycin (K-30), and streptomycin (S-10). These 
results agree with literature findings that C. sakazakii is sensitive to gentamicin, ampicillin, 
chloramphenicol, kanamycin, and streptomycin and others while showing resistance to beta 
lactam drugs such as cephalothin(3, 19, 32, 37) .However, some strains of C. sakazakii have 
been found to be resistant to tetracycline (Te-30), which is not consistent with this study (19). 
 
 
 
Table 3: Antibiotic Susceptibilities  
Isolate Te-
30 
Amc-
30 
C-
30 
Gm 
10 
Ceftiofur CF-
30 
K 
-
30 
S-
10 
Am- 
10 
An-
30 
Sulfisoxazole Na-
30 
DH5α S S S S S S S S S S S I 
K1 S S S S S S S S S S S S 
52 S S S S S R S S S S S S 
BAA 
894 
S S S S N/A R S S S S N/A S 
CT2 S S S S S R S S S S S S 
N72 S S S S S R S S S S S S 
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Bacterial Growth 
 Experimental procedures for the cytotoxicity and supernatant assays were carried out 
under static conditions at 37
o
 C and 5% CO2. In order to approximate the growth rate of the 
bacteria in LB broth under these conditions, the OD600 of individual isolates was measured 
hourly when kept at static conditions and 37
o
 C. Plates counts were also taken hourly to assess 
the doubling time of bacteria.  
 The negative E. coli control DH5 α shows a delayed lag phase when compared to the 
positive K1 control as seen in Figure 2 below. Both isolates show normal growth curves with 
characteristic log and stationary phases. The doubling time for each strain was calculated using 
the equation : G= t/3.3 logb/B where: t equals time, b equals number of bacteria at endpoint, and 
B equals number of bacteria at startpoint (65). According to plate count data used with these 
calculations, under static growth at 37 
o
 C E. coli DH5 α doubles approximately every 31 
minutes while K1 doubles approximately every 43 minutes. The calculated doubling times do not 
agree with the appearance of the growth curve which suggests the K1 isolate grows at a faster 
rate than the DH5 α. This discrepancy is most likely due to plating inefficiency of dilutions used. 
The Bacterial Analytic Manual (BAM) recommends that plate counts between 25-250 colony 
forming units (cfu) be used for best results; most statistical analysis uses an n of 30 as a 
statistically significant figure (69, 70). Despite plating multiple dilutions, colony counts within 
the accepted range were not always found; some results report fewer than 25 cfu/ml.  This could 
greatly affect the accuracy of the plate counts and account for the seemingly disparate doubling 
times. Overall, the estimated doubling times of both E. coli strains in this study remain within the 
same time frame of the accepted doubling time of E. coli under optimal conditions with shaking 
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which is 20 minutes (61). The longer doubling time is expected as the optimal doubling time of 
E. coli is calculated with shaking, whereas this study used static conditions which results in a 
loose pellet at the bottom of culture tubes versus a homogenous mixture throughout the tube. 
 
Figure 2: E. coli Growth Curve at 37
o
 C in LB Broth Under Static Conditions. The X axis 
measures time in hours and the Y axis represents the OD600 reading on a logarithmic scale. The 
K1 isolate quickly moves into log and stationary phase. DH5 α shows a similar growth pattern 
with delayed lag and log phase in comparison to K1. 
 The C. sakazakii experimental isolates 52, BAA 894, CT2, and N72 all show uniform 
growth curves that tightly cluster between isolates as shown in Figure 3 below. The calculated 
doubling times of the isolates are as follows: Isolate 52, approximately 16 minutes; BAA 894, 
approximately 12.5 minutes; CT2, approximately 14 minutes; and N72, approximately 17 
minutes. These doubling time values are likely an underestimation of the true doubling time as 
the plate count method did not always produce cfus in the countable range which forced the use 
of colonies counts under 25. Iverson et al report that Cronobacter Complexhave an average 
doubling time of 22 minutes at 37
o
 C (17) . The C. sakazakii doubling time values reported 
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above fall closely within this range. The discrepancy between the reported doubling time and 
those found in literature of E. sakzakii (Cronobacter species) and the isolates used in this study 
are most likely due to plating inefficiency. 
 
Figure 3: C. sakazakii Growth Curve at 37
o
 C in LB Broth Under Static Conditions. The X axis 
measures time in hours and the Y axis represents the OD600 reading on a logarithmic scale. All 
isolates appear to cluster closely showing uniform growth from lag and log phase into stationary 
phase.  
 Below, Figure 4 shows the combined growth curves of all E. coli and C. sakazakii 
isolates. The combined figure shows that the K1 isolate has a quicker growth rate than the 
clustered C. sakazakii isolates while the DH5 α isolate grows slowest. Again, the discrepancy 
between the calculated doubling times, which estimates a much faster doubling rate for the C. 
sakazakii isolates, is due to plating inefficiency; the OD600 readings plotted against time more 
accurately reflect the actual growth of the isolates. 
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Figure 4: Combined Growth Curves of E. coli and C. sakazakii Isolates. The OD600 values are 
plotted on a logarithmic scale vs time in hours. All isolates show similar growth patterns with the 
positive K1 control showing a slightly increased rate and the negative DH5 α control showing a 
decreased rate of growth in log phase.  
 Both the E. coli isolates used as assay controls and the experimental C. sakazakii isolates 
used show standard growth patterns fall within the accepted doubling time ranges of their 
representative species. In terms of growth, all isolates were deemed to grow at similar rates. This 
excludes slow growth as a reason for differences seen between cytotoxicity over time.  
Bacterial Motility 
 To further characterize E. coli and C. sakazakii isolates, bacterial motility was analyzed 
at two temperatures 25
o
 C and 37
o
C. Bacterial movement in motility agar gives an indirect 
method to determine whether flagella are expressed and allows calculation of movement rate in 
millimeters per hour. The expression of flagella may contribute to bacterial pathogenesis and 
further analysis can be performed to determine the structural role of these structures in 
contribution to disease. Motility was assessed using the swarm plate method as described by 
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Wolfe and Berg (62). Individual isolates were aseptically inoculated into the center of each 
motility plate and stored at 25
o 
C and 37
o
 C, respectively with swarming rings measured hourly. 
 The E. coli isolates show contrasting motility patterns as shown in Figure 5 Below. K1 
exhibits motility at 25
oC while DH5α is non-motile. The rates of motility for K1 and DH5α at 
25
o
 C are 2.74 mm/hr and 0 mm/hr, respectively.  
 
Figure 5: E. coli Motility at 25
o
 C on Swarm Plates. Motility is plotted with movement in 
millimeters (mm) vs. time in hours. K1 shows motility at a rate of 2.74mm/hr while DH5α is 
non-motile. 
 C. sakazakii isolates were all found to be motile at 25
o
 C, although rates of motility 
differed between strains. Figure 6 shows the variation between strains. Isolate motility at 25
o
 C is 
as follows: 52: 2.43 mm/hr; BAA 894: 6.9mm/hr; CT2: 2.37 mm/hr; N72 1A: 2.925 mm/hr. 
BAA 894 shows the highest rate of motility at this temperature while the other isolates exhibit 
motility rates similar to E. coli K1 under the same conditions. Cronobacter Complex are 
generally motile (3, 4).  
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Figure 6: C. sakazakii Motility at 25
o
 C on Swarm Plates. Motility is plotted with movement in 
millimeters(mm) vs time in hours. All C. sakazakii isolates are motile at these conditions, with 
BAA 894 exhibiting the highest rate of motility at 6.9mm/hr. 
 The positive and negative E. coli controls show contrasting motility patterns at 37
o
 C as 
well, which can be seen in Figure 7. K1 exhibits motility while DH5α is non-motile. The rates of 
motility for K1 and DH5α at 25o C are 4.34 mm/hr and 0 mm/hr, respectively.  
 
Figure 7: Figure 4: E. coli Motility at 37
o
 C on Swarm Plates. Motility is plotted with movement 
in millimeters (mm) vs. time in hours. K1 shows motility at a rate of 4.34 mm/hr while DH5α is 
non-motile. 
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 C. sakazakii isolates were all found to be motile at 37
o
 C, although rates of motility 
differed between strains as seen in Figure 8. All isolates showed increased motility at this 
temperature compared to motility at 25
o
 C. Isolate motility at 37
o
 C is as follows: 52: 9.8 mm/hr; 
BAA 894: 15.44 mm/hr; CT2: 6.62 mm/hr; N72 1A: 13.33 mm/hr. BAA 894 again shows the 
highest rate of motility at this temperature with N72 1A also showing a similarly high rate. 
Isolates 52 and CT2 show lower rates of motility but these are still higher than that of E. coli K1 
at the same temperature. 
 
Figure 8: C. sakazakii Motility at 37
o
 C on Swarm Plates. Motility is plotted with movement in 
millimeters (mm) vs time in hours. All C. sakazakii isolates are motile at these conditions, with 
BAA 894 and N72 1A both exhibiting the highest rates of motility at 15.44 mm/hr and 13.33 
mm/hr, respectively. 
Cytotoxicity Assays 
 The cytotoxicity assays measured bacterial ability to disrupt and or damage the mouse 
endothelial cell line over a time course of 48 hours. Confluent endothelial (EOMA) cells were 
inoculated with 10
8
 cfu/ml from overnight bacterial cultures. Different bacterial isolates were 
pipetted into individual chambers of the chamber slide and all chamber slides were incubated at 
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37
o
C 5% CO2. Slides were processed and stained at three time points, 24 hours, 36 hours, and 48 
hours, and stained with either diff-quick or hemotoxylin. All slides were viewed on a bright field 
microscope and imaged at 200x, 600x, and 1000x magnification. Representative images from the 
larger 200x field of view are shown in the following figure to illustrate EOMA confluency and 
cell morphology after incubation with bacterial isolates. 
 E. coli K1 was used as a positive control while DH5 α served as the non-pathogenic 
negative control. C. sakazakii isolates 52, BAA 894, CT2, and N72 1A were used to assess 
damage to EOMA cells. With respect to damage to EOMA cells, relative confluency and 
morphology of the EOMA cells is qualitatively compared. The bacterial aggregation patterns and 
changes in EOMA cell morphology were compared between control and test isolates. At the 
initial 24 hour time point, C. sakzakii isolates show very little damage to EOMA cells and most 
closely resemble the DH5 α control. However, the C. sakazakii isolates showed increased 
damage to EOMA cells over time, showing similar levels of damage at 48 hours as the K1 
control. 
 Figures 9-14 below show EOMA cell controls, E. coli positive and negative controls, and 
C. sakazakii test isolates. 
Figure 9 shows that the DH5 α negative control shows no apparent damage to EOMA 
cells at any time point. The EOMA cells remain 100% confluent and retain normal cell 
morphology.  
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Figure 9: EOMA Cytotoxicity Assay Control. A confluent monolayer of EOMA cells at 24, 36, 
and 48 hours at 200X magnification. Cells remain 100% confluent and retain normal 
morphology. 
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In Figure 10, the E. coli  cytotoxicity patterns can be seen for both the positive and 
negative meningitis causing controls.The positive K1 control shows increasing damage to 
EOMA cells at all time points investigated. Initially, at 24 hours, EOMA cells show reduced 
confluency and the cells begin to show a rounded morphology and K1 cells can be seen in both 
cell-free areas and clustered on top of remaining cells. At 36 hours, cell confluency is further 
reduced and K1 cells cover a majority of the slide surface obscuring remaining EOMA cells; cell 
confluency remains around 75%.  At 48 hours, EOMA cell confluency is reduced to 
approximately 25%. Again, K1 cells appear clustered in both cell-free areas and aggregated over 
the remaining EOMA cells.  
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Figure 10: E. coli Cytotoxicity Assay Control. The left panel shows DH5α at 24, 36, and 48 
hours at 200X magnification; the right panel shows K1 at the same time points and 
magnification.  
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Below, Figure 11 shows C. sakazakii BAA 894 in the right-hand panel at each time point. 
K1 is shown on the left at corresponding time points for comparison. Initially, no apparent 
damage is seen at the 24 hour time point. The EOMA cells remain 100% confluent with normal 
cell morphology. However, after 36 hours BAA 894 shows significant damage to the EOMA 
cells. EOMA confluency is reduced below 50% and remaining cells begin to show rounding. 
BAA 894 cells can be seen aggregated around EOMA cells and dispersed in cell free areas. At 
this time point, the BAA 894 isolate shows more damage than the K1 positive control, which did 
not decrease EOMA confluency below 50%. In addition, the bacteria appear to behave 
differently when in contact with EOMA cells. The K1 control aggregates on top of and around 
the EOMA cells while BAA 894 aggregates around EOMA cells only. At 48 hours BAA 894 
reduces EOMA cell confluency below 25% leaving remaining EOMA cells with abnormal and 
rounded morphologies. Again, the damage caused by BAA 894 is more severe than that of the 
K1 control. BAA 894 cells can still be seen near EOMA cells, although clustering is not as 
evident. Few cells remain on the slide. In contrast, the K1 cells still aggregate on top of an 
around EOMA cells and show great cell numbers throughout the slide at 48 hours.  
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Figure 11: BAA 894 Cytotoxicity Time Course. The panel on the left shows C. sakazakii BAA 
894 at 24, 36, and 48 hours at 200X magnification; the right panel shows K1 at the same time 
points and magnification. 
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Figure 12 shows C. sakazakii 52 in the right-hand panel at each time point. K1 is shown 
on the left at corresponding time points for comparison. This isolate initially shows no apparent 
damage or reduction in EOMA confluency at 24 hours but begins to show increasing adverse 
effects after 36 and 48 hours. At 36 hours, isolate 52 causes a reduction in EOMA cell 
confluency similar to that of K1 at the same time point: approximately 75% confluency. EOMA 
cells begin to show more rounded morphology. At 36 hours isolate 52 cells appear to both 
aggregate on top of and around the EOMA cells in a similar fashion to K1. Some cells can be 
seen diffused in cell-free spaces. At 48 hours, isolate 52 reduces EOMA cell confluency below 
25% similar to K1. Here, isolate 52 cells aggregate around and on top of EOMA cells with some 
aggregated cells in EOMA cell-free areas.  
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Figure 12: 52 Cytotoxicity Time Course. The panel on the right shows C. sakazakkii 52 at 24, 
36, and 48 hours at 200X magnification; the right panel shows K1 at the same time points and 
magnification. 
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Figure 13 shows C. sakazakii CT2 in the right-hand panel at each time point. K1 is shown 
on the left at corresponding time points for comparison. The results in this time course are not as 
consistent as those of other C. sakazakii isolates. At 24 hours, no apparent EOMA cell damage 
can be seen when inoculated with CT2. After 36 hours, a high degree of damage is seen with 
EOMA cell confluency reduced below 50%. Remaining EOMA cells are obscured by CT2 cells 
aggregated around and on top of the EOMA monolayer. At this time, CT2 causes a greater 
reduction in EOMA cell confluency than K1. However, this isolate showed varying results 
between experimental repetitions with some trials showing high degrees of damage at 36 and 48 
hours while showed none. The 48 hour time point shown in Figure 13 represents an experimental 
run where little to no damage was seen even after 48 hours. The EOMA monolayer remains 
nearly 100% confluent with normal cell morphology.  
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Figure 13: CT2 Cytotoxicity Time Course. The panel on the right shows C. sakazakkii CT2 1A 
at 24, 36, and 48 hours at 200X magnification; the right panel shows K1 at the same time points 
and magnification. 
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Figure 14 shows C. sakazakii N72 1A in the right-hand panel at each time point. K1 is 
shown on the left at corresponding time points for comparison. The results in this time course 
show increasing pathogenic effects after 36 hours with damage similar to the K1 control. At 24 
hours, no apparent EOMA cell damage can be seen when inoculated with N72 1A. After 36 
hours, damage to EOMA cells can be seen in terms of a reduction in confluency, changes in cell 
morphology, and high numbers of bacterial cells. The EOMA cell monolayer shows a slight 
reduction, but remains over 75% confluent. N72 1A cells appear to stack on top of and clustered 
around the EOMA cells. At 48 hour time point, a greater reduction in EOMA cell confluency can 
be seen. EOMA cells show 50% confluency as compared to 25% confluency with the K1 
control. In both the N72 1A and K1 48 hour time points EOMA cells show great cell rounding 
and reduced cell-cell contact. Bacterial cells appear to cluster on top of and clustered around the 
remaining cells in the monolayer. 
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Figure 14:N72 1A Cytotoxicity Time Course. The panel on the right shows C. sakazakkii N72 
1A at 24, 36, and 48 hours at 200X magnification; the right panel shows K1 at the same time 
points and magnification. 
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Supernatant Assays 
 The supernatant assays measured bacterial ability to disrupt and or damage the mouse 
endothelial cell line over a time course of 48 hours using concentrated supernatant from 
individual overnight bacterial cultures in LB. Confluent endothelial (EOMA) cells were 
inoculated with 2 mls concentrated bacterial supernatant that was filtered through a 3 micron 
filter and syringe. Endpoint supernatant was plated to ensure that no live bacteria were present. 
Different supernatants from isolates were pipetted into individual chambers of the chamber slide 
and all chamber slides were incubated at 37
o
C 5% CO2. Slides were viewed live on a differential 
interference contrast (DIC) microscope at, 24 hours, 36 hours, and 48 hours. All slides were 
imaged at 200x magnification. Representative images from are shown in the following figure to 
illustrate EOMA confluency and cell morphology after incubation with bacterial isolates. 
 E. coli  K1 was used as a positive meningitis-causing control while DH5 α served as the 
non-pathogenic negative control. C. sakazakii isolate BAA 894 was chosen to assess damage to 
EOMA cells due to its ability to reduce EOMA cell confluency to a high degree and because it is 
known to cause meningitis (71, 72). With respect to damage to EOMA cells, relative confluency 
and morphology of the EOMA cells is qualitatively compared. The EOMA cell morphology was 
also compared between control and test isolates. Both the supernatant-free EOMA cell control 
and the negative DH5 α control, seen in Figure 15, show now apparent damage to the monolayer 
of EOMA cells at any time point. The K1 negative control does not show damage to the 
monolayer early on (Figure 16), but after 36 hours, EOMA cell rounding and reduced confluency 
can be seen. At the Initial 24 hour time point the supernatant from BAA 894 (Figure 16) begins 
to show damage to the EOMA monolayer whereas the K1 control does not.  
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Figures 15-16 below show EOMA cell controls, E. coli positive and negative controls, 
and C. sakazakii BAA 894 at 24, 36, and 48 hour time points. 
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Figure 15: Supernatant Controls. The panel on the right shows EOMA supernatant-free control 
at 24, 36, and 48 hours at 200X magnification; the left panel shows DH5α supernatant at the 
same conditions.  
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 Figure 16 shows the C. sakazakii BAA 894 supernatant assay on the right and the K1 E. 
coli control on the left at 200x magnification. At 24 hours, the K1 supernatant control shows a 
slight reduction in EOMA cell confluency with cells remaining overall confluent with normal 
morphology. In contrast, BAA 894 supernatant causes marked reduction in EOMA cell 
confluency at 24 hours. The monolayer appears slightly over 50% confluent with remaining cells 
showing more “stretched” cell shape than usual.  At 36 hours, the K1 supernatant control begins 
to show a reduction in EOMA cell confluency and shows a change in cell morphology. The 
confluency remains above 75%, however the remaining attached EOMA cells begin to show 
rounding. Some detached dead cells can be seen. Before the image is captured from the live 
view, round (dead) cells are apparent from movement while attached cells remain fixed in view. 
At 36 hours, the BAA 894 supernatant shows reduced cell confluency below 25%. Remaining 
EOMA cells in the image are floating dead cells that have detached from the slide. Once the 48 
hour time point is reached, more dead and floating cells can be seen with the K1 supernatant 
control. EOMA confluency is reduced to under 25% and few attached cells can be seen. BAA 
894 supernatant shows nearly all EOMA cells to be dead and floating. Few remaining EOMA 
cells can be found attached to the slide at this time.  
 The supernatant assay shows time scale differences between the E. coli and C. sakazakii 
damage to EOMA cells as well illustrating cytotoxicity can be mediated by cell-free supernatant 
alone.  
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Figure 16: BAA 894 Supernatant Time Course. The panel on the right shows C. sakazakii BAA 
894 supernatant at 24, 36, and 48 hours at 200X magnification; the right panel shows K1 
supernatant at the same time points and magnification. 
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Gentamicin/ Adhesion Assays 
 The Gentamicin and Adhesion Assays were performed to determine bacterial isolate 
ability to adhere to and invade EOMA cells as described by Berry et al (64). The original assay 
was designed to be used with uropathogenic E. coli and monolayers of mouse bladder cells (64). 
In addition to the E. coli controls and C. sakazakii isolates, S. enterica was used as an invasive 
control. When used with the EOMA cell line and C. sakazakii isolates, bacterial cells could not 
be detected at the endpoint of either the adhesion or gentamicin assay (data not shown).  
 Troubleshooting measures tested differented percentages of chemicals used and higher 
multiplicities of infection (MOI). It was determined that concentrations of chemicals used in the 
experiment were not affecting the bacterial cells. However, the multiplicity of infection and 
incubation times had marked effects on the ability to detect bacteria at experimental endpoints. 
The original protocol calls for a two hour incubation and MOI of 10. When given longer 
incubation times and higher MOI, endpoint bacterial cell counts could be detected (data not 
shown). An MOI of 10
2
 or 10
3
 is recommended with the use of all incubation times.  
Due to time constraints and EOMA cell culture failure, these experiments with improved 
parameters were not able to be performed in triplicate. Therefore there is no data available for 
these procedures. 
  
48 
 
DISCUSSION 
Experimental Model 
 Research in the Gibbs lab has focused on the development of an in-vitro system to study 
C. sakazakii invasion of the blood brain barrier through the use of an astrocyte and brain 
microvascular endothelial cell co-culture. This system utilizes trans endothelial electrical 
resistance (TEER) to measure the integrity of an intact barrier and to detect breeches in the 
barrier observed by reduced resistance. This system can be applied to identify isolates of 
bacterial species that are able to breech the barrier as well as aid in identifying the time course of 
barrier breech. Identification of crucial barrier time-points can be used to study: proteins 
expressed by bacteria at this time, gene expression levels, and may also be used to compare 
genotypes of virulent vs. non-virulent isolates within the species. 
 This MS thesis aimed to provide time-course image analysis of changes made to the first 
cells C. sakazakii would encounter in vivo, brain microvascular endothelial cells. In addition,  
known meningitis causing C. sakazakii isolates (BAA 894 and CT2) and fecal isolates (52 and 
N72 1A) were used to characterize phenotypic similarities and differences between isolates. All 
isolates showed similar growth rates, resistance to antibiotics, and showed great motility. The 
ability of individual isolates to damage monolayers of mouse endothelial cells (EOMA) varied 
by isolate and with incubation time. BAA 894 showed the greatest level of cell damage at rates 
that exceeded the E. coli K1 control, while other isolates required more time and caused less 
damage. In addition, EOMA cell damage was shown to occur independently of live C. sakazakii 
with the use of BAA 894. Adhesion and invasion of EOMA cells was not able to be determined 
using the existing protocol, but new parameters were investigated. 
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Blood Brain Barrier Invasion Requirements 
 In order for a pathogen to cause meningitis, it must first complete a number of steps 
including colonization of the tissue of entry, invasion of surrounding cells, survival and 
multiplication resulting in spread to the blood, and finally, entry into the brain by crossing the 
blood brain barrier (56, 57). Research suggests that C. sakazakii achieves these steps via an oral 
route through an initial contact with contaminated powdered infant formula followed by 
colonization and invasion of the gut epithelial cells leading to bacteremia (39, 59).  
Once in the bloodstream, the bacteria not only survive but also maintain high levels 
before adherence to brain microvascular endothelial cells; Invasion of the barrier also requires 
cytoskeletal rearrangements and traversal as live bacteria (60). To mimic high rates of 
bacteremia, an inoculum of 10
8
 bacterial cells/ml were used in cytotoxicity assays. Research 
revealed that 10
3
 cfu/ml may be more appropriate as this is the level of bacteremia needed to 
cause meningitis in neonates (57). These assays showed that the mouse microvascular 
endothelial cells were unable to maintain cell confluency over time when co-cultured with C. 
sakazakii isolates (Figures 11-14). High levels of bacteria could affect confluency either by 
direct or indirect EOMA cell contact. Cytotoxicity assays showed that C. sakazkii isolates appear 
to cluster around cells and to fill the space between the cells. This could indicate that direct 
adhesion occurred; further studies of ligand-receptor interactions would elucidate the cell 
components involved.  
In addition, the supernatant assays showed that live bacterial cells were not needed to 
cause EOMA cell damage and disruption of confluency (Figure 16). This indirect cause of 
damage is most likely due to LPS in combination with toxin(s).  
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Certain isolates of Enterobacter.(Cronobacter species) have been shown to adhere to 
brain microvascular endothelial cells (BMEC) in either diffuse or clustered patterns (51). In 
addition, isolates of C. sakazakii show isolate specific ability to invade BMECs at low, 
intermediate, and high levels (39).  The new parameters for the Adhesion and Gentamicin assays 
will aid in determining two key points: 1) whether the isolates used are able to adhere and invade 
cells and 2) whether the mouse EOMA cell line is a suitable for use to represent blood brain 
barrier invasion in humans. If the EOMA cell line does not result in the same interactions seen in 
human brain microvascular endothelial cells, then an alternate cell line may be needed for more 
accurate representation.  
Studies have also shown that C. sakazakii invasion of BMECs utilize signal transduction 
pathways associated with Akt/P13K pathway leading to cytoskeleton rearrangements (49, 50). 
Determining genetic differences between invasive versus non-invasive phenotypes of C. 
sakazakii may aid in identification of crucial factors necessary for invasion. These may include: 
ligand/receptor interactions or virulence factors that could induce such signaling. Utilizing stains 
specific for the cytoskeleton in conjunction with the current cytotoxicity assays could enable 
visualization of the process taking place.  
Overall, the initial cytotoxicity and supernatant assays show that C. sakazakii isolates are 
able to grow in co-culture with the EOMA cell line and to cause substantial cell damage over 
time. The meningitis causing strains BAA 894 (Figure 11) and CT2 (Figure 13) showed 
considerable variation in their ability to cause damage to the cell monolayer. BAA 894 caused a 
substantial reduction in cell confluency within the first 24 hours of incubation; whereas; CT2 
showed varying ability to damage the cell monolayer at all. These differences may be due to 
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differences between isolates or could indicate that the two isolates utilize different pathways to 
cross endothelial cells. It is interesting to note that the environmental isolates 52 (Figure 12) and 
N72 1A (Figure 14) both showed a consistent ability to damage EOMA cell confluency over the 
24, 36, and 48 hour time points. These isolates have not been shown to cause meningitis, but 
through the use of the astrocyte-endothelial TEER system, may be shown to be pathogenic in 
vitro. Conversely, if these isolates are unable to penetrate the in vitro system, differences 
between meningitis and non-meningitis causing isolates may be elucidated. 
Understanding differences and mechanistic pathways of invasion between pathogenic and 
non-pathogenic strains of bacteria could provide targets for novel treatment and prevention of 
infection.  
BBB Pathogens  
 Pathogens may invade the blood-brain barrier in three different ways: transcellularly, 
paracellularly, or via survival in infected phagocytic cells (53, 60). Transcellular traversal of the 
blood brain barrier occurs when bacteria travel through an individual cell while paracellular 
transport involves movement between two adjacent cells (53).  
 C. sakazakii may be able to use multiple methods of traversal as suggested by its ability 
to invade both macrophages and brain microvascular endothelial cells (39, 45). Invasion of 
BMECs may indicate transcellular traversal while invasion of macrophages could support 
phagocytic transport. The present studies focus on investigating a transcellular mechanism in C. 
sakazakii. To investigate this pathway, EOMA cell invasion must be confirmed to ensure that the 
cell line is suitable for a human model. New parameters for use with the Invasion assay will be 
able to determine this ability in the future. Next, the molecular details of invasion and possible 
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cytoskeletal rearrangement can be characterized. In addition, further work with the cytoxicity 
and supernatant assays may aid in identifying key bacterial interactions or products necessary for 
live traversal of the blood brain barrier. 
Meningitis causing pathogens of both prokaryote and eukaryote origin have been 
extensively reviewed and shown to use or are predicted to use one or a number of pathways as 
summarized in Table 4 below. 
Table 4: Traversal of the Blood Brain Barrier  
Organism Domain Mechanism of Traversal 
Borrelia 
burgdorferia 
Prokaryote Paracellular (53, 60) 
Transcellular  (54) 
Trypanosoma 
species 
Eukaryote Paracellular (53, 54) 
Listeria 
monocytogenes 
Prokaryote Phagocytic Transport as Live Bacteria (53, 
54, 60) 
Transcellular (53, 54, 60) 
Mycobacteria 
tuberculosis 
Prokaryote Phagocytic Transport as Live Bacteria (53, 
54, 60) 
Transcellular (53, 54, 60) 
Eschericia coli Prokaryote Transcellular (53, 54, 60) 
Neisseria 
meningitidis 
Prokaryote Transcellular (53, 54, 60)  
Group B 
Streptococci 
Prokaryote Transcellular (53, 54, 60) 
Candida albicans Eukaryote Transcellular (53, 54, 60) 
Mechanisms of Blood Brain Barrier Traversal by various meningitis causing prokaryotic and 
Eukaryotic organisms. 
 These pathogens are able to breach the BBB using various pathogen-specific host-
microbe interactions including specific ligand-receptor interactions, activation of cytoskeleton 
signaling pathways, activation of host immune system and through the utilization of specific 
microbial proteins (53, 54, 56, 57). 
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 As additional information on C. sakazakii is accumulated, comparison to other 
meningitis-causing pathogens may aid in identifying similar pathway sequences.  
Escherichia coli K1 As A Model Organism 
 E. coli K1 is an encapsulated strain of E. coli that is able to survive in the blood, invade 
human brain microvascular endothelial cells (HBMEC), and can cause meningitis. It is often 
used as a model organism in both in vitro and in vivo meningitis studies (53, 57, 60) and served 
this purpose in this in vitro study. The transcellular invasion of E. coli K1 across the BBB has 
not been fully elucidated, although many bacterial components necessary for invasion have been 
discovered. After causing high levels of bacteremia in the blood, E. coli K1 must survive host 
immune defenses and both attach and invade HBMECs.  K1 is able to survive in the blood due to 
the K1 antigen which provides serum resistance of bacterial killing (53, 57).  To then attach to 
HBMECs, K1 utilizes Type 1 fimbrae, outer membrane protein OmpA, CNF1, and IbeB which 
provide adhesion and receptor-ligand attachment, and invasive ability (53, 57, 73–76). The 
bacterium then uses a transcellular “zipper” mechanism to trigger cytoskeletal rearrangements 
through the use of signal transduction pathways utilizing FAK, P13K, Src and Cpla2 (60, 73). 
Following cytoskeletal rearrangement, E. coli K1 survives in host vacuoles without replicating 
until crossing the barrier as live bacteria (57). These components have been compiled in Table 5 
below. 
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Table 5 :E. coli K1 Requirements for BBB Invasion 
Component Bacterial Function Aid In BBB 
K1 Capsule Serum Resistance (53, 57) 
FimH Adhesional Fimbraie  Binds HBMECs (53, 57) 
OmpA Outer membrane protein Binds N-acetyl-glucosamine of 
HBMEC (53, 57, 73, 74) 
IbeB Invasion Locus Aids in HBMEC invasion (53, 
57, 74, 75) 
Cytotoxic necrotizing factor 1 
(CNF1) 
Toxin Aids in HBMEC Invasion (53, 
57, 76) 
E. coli K1 Components and their contributions to BBB invasion. 
 In an in vitro model, K1 strain RS218 does not disturb the HBMEC monolayer after 60 
minute incubation, whereas in non-endothelial cell lines this strain causes cell rounding (77).  
The study utilized a monolayer of endothelial cells and TER with an MOI of 10 and showed that 
after the initial two hours of infection the monolayer retained cell morphology and initially 
increased electrical resistance (77).  
The present investigation of mouse microvascular endothelial cells utilized time points 
beyond 2 hours to detail cell damage after 24, 36, and 48 hours of incubation. As detailed in cell 
control Figure 9, E. coli K1 begins to cause increasing damage and cell rounding to the 
monolayer of endothelial cells ending with a qualitative estimation of 75% loss in monolayer 
confluency after 48 hours. The DH5   non-pathogenic control does not cause any apparent 
damage to endothelial cell monolayers at any time point. Previous studies from the Gibbs lab 
using the TEER co-culture of both endothelial cells and astrocytes indicate that the electrical 
resistance decreases over time after incubation with E. coli K1 (Welker and Gibbs, unpublished). 
Taken together with the cytoxicity assay showing increasing endothelial cell damage over time, 
these findings indicate that the endothelial barrier cannot sustain long-term exposure to this 
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organism. In terms of patient treatment, eliminating the infection after barrier traversal remains 
crucial to patient survival. 
When researching in vivo models of E. coli K1 associated studies, RS218 was found to be 
used as a common control. Further investigation into the current K1 strain utilized for cell 
controls in the present assays revealed that the ATCC isolate 11775 is a BSL 1 organism and 
may not be associated with bacterial meningitis. This could mean that the results seen in these 
studies do not accurately reflect what is seen with a true meningitis causing K1 isolate. It is 
recommended that a proven meningitis-associated isolate such as RS218 be used as the positive 
meningitis causing control for future work with both monolayer and co-culture studies in the lab. 
This will ensure that the cytotoxic effects seen by the meningitis causing control are accurately 
represented. 
C. sakazakii Characterization  
 The C. sakazakii isolates 52, BAA 894, CT2, and N72 1A were all shown to share similar 
physiological characteristics in terms of growth and antibiotic susceptibility as shown in Figure 2 
and Table 3. Strains 52 and N72 1A were fecal isolates from bovine and bison respectively. BAA 
894 is a meningitis-associated isolate obtained from the ATTC, while CT2 is also a meningitis-
associated isolate from a clinical source. All C. sakazakii isolates appear to grow normally and at 
similar rates to the E. coli isolates used. With respect to the time course investigation, this 
excludes slower growth as reason for delayed damage during the time course investigation. 
Differences seen in cytotoxicity over time are a result of other differences between the bacteria. 
The antibiotic susceptibility patterns observed overall agree with what is found in the literature 
with respect to C. sakazakii sensitivities and resistance.  
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 All isolates of C. sakazakii were also shown to be motile through the use of swarm plates 
(Figures 6 & 8) at both 25 and 37 
o
C. All isolates were shown to be more motile at 37
o
C and 
BAA 894 showed the highest rates of motility at both temperatures. The significance of isolate 
motility is most likely important in food processing, and initial infection during necrotizing 
enterocolitis. 
Cytotoxicity Variation 
 Cell cytotoxicity varied between isolates with BAA 894 showing earlier damage than 
other isolates and causing the greatest reduction in EOMA cell monolayer confluency. 
Surprisingly, the clinical meningitis-causing isolate CT2 showed varying ability to damage the 
EOMA cell monolayer between experimental trials. During some trials a high degree of damage 
was seen, while during experimental repeats at other times no damage was observed. This could 
be due to experimental error or could be due to variation in the isolate’s ability to consistently 
express factors necessary for cell damage. Alternately, isolate CT2 may cause meningitis through 
survival in phagocytic cells, bypassing the need for direct barrier contact. BAA 894, 52, and N72 
1A all showed increased damage to EOMA cell monolayers over time as shown in Figures 11-12 
and 14. Figure 13 shows the variable ability of CT2 to damage the EOMA cell monolayer.  
 The mechanism that C. sakazakii uses to traverse the BBB is unknown. However, both 
transcellular and phagocytic traversal appear possible. C. sakazakii is able to invade HBMECs, 
possesses OmpA, and causes cytoskeletal rearrangement which would support transcellular 
traversal (53). Alternately, the organism’s ability to survive within macrophages could facilitate 
penetration after surviving phagocytosis (53).  As shown in Table 4, some pathogens utilize more 
than one pathway to cross the BBB therefore C. sakazakiii could do the same. 
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 Two methods of transcellular BBB penetration are possible using either the “zipper” or 
“trigger” mechanism; The zipper mechanism requires direct cell contact while the trigger 
mechanism acts through indirect contact (60). As described above, E. coli K1 utilizes OmpA for 
direct HBMEC contact. Studies have shown C. sakazakii requires OmpA and OmpX for invasion 
of intestinal epithelial cells which supports the use of  the zipper mechanism (40).Invasion of 
endothelial cells has also been shown to be dependent on these OmpA, although it’s interaction 
with HBMECs receptors may differ from that of K1 (78). Different mechanisms could be used 
by C. sakazakii for different cell types. Staining the cytoskeleton in conjunction with this assay 
may show whether direct bacterial contact occurs which would support the zipper mechanism. 
These images would show whether direct contact or “ruffling” occurs. 
Supernatant Cytotoxicity Investigation 
 To begin to investigate an indirect mechanism and to further detail monolayer damage, 
cell-free supernatant cytotoxicity assays were performed. As the only consistently cytotoxic 
meningitis-causing isolate, BAA 894 was chosen for further use. Confluent monolayers of 
EOMA cells were inoculated with cell-free BAA 894 supernatant from an overnight culture. 
Figure 16 details the early damage caused to the monolayer at 24 hours and near-complete 
destruction of the monolayer after 48 ours. These findings suggest toxin-mediated damage to the 
EOMA cell lines. This damage could be a result of a single toxin or multiple toxins acting 
together. Separating supernatant components by cell fraction via high performance liquid 
chromatography would aid in isolation of the damaging toxin(s). Toxin-mediated entry into 
EOMA cells would support the trigger mechanism of entry.  
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Significance to Society 
 Bacterial meningitis causes approximately 1.2 million cases/year worldwide and 
contributed to approximately 393,000 deaths in neonates in 2010 (79, 80). Newborns and 
children are at higher risk for bacterial meningitis as well as those in developing nations or with 
compromised immune systems (80). While C. sakazakii’s contributions to these rates may be 
small, it has been recognized as an emerging pathogen (28, 59). Understanding the mechanisms 
of blood brain barrier traversal in C. sakazakii may contribute to existing knowledge of bacterial 
mechanisms which may in turn contribute to prevention, control, and treatment measures. 
Investigating the main cell lines involved in the BBB will establish the groundwork for this 
understanding. 
 The link between contaminated infant formula and C. sakazakii associated neonatal 
meningitis underscores the need for understanding disease development in infants. The blood 
brain barrier develops from the neonatal to adult stages resulting in a progressive tightening of 
the barrier (52). Identifying the components of the BBB targeted by these bacterial cells will 
enhance our understanding of the disease mechanism and will allow for comparison between 
neonatal and adult barriers. Identifying whether key features make neonates more susceptible to 
invasion will provide a target for prevention and treatment. 
 Further, development of an in vitro mouse system for the study of the major cell lines 
involved in BBB formation may be widely used with other species. As the molecular details of 
bacterial traversal are elucidated, bacterial isolates can be studied with respect to their ability to 
cause the same damage in knockouts. Additionally, in a meningitis outbreak situation, suspected 
environmental isolates could be screened using the system to assess the potential to damage brain 
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microvascular endothelial cells and astrocytes. If reliable, such an assessment would contribute 
to the identification of the causative agent of disease.  
Future Work 
 Several future studies could expand upon the work presented in this thesis including: 
identifying receptors involved in bacterial adhesion, further investigation into the possibility of 
toxin mediated damage, and biofilm investigation. 
 Utilizing a higher MOI (10
2
-10
3
) with the Gentamicin/Adhesion assay will show the 
degree of bacterial adhesion to EOMA cells as well as whether C. sakazakii is able to invade the 
mouse cell line. This will allow for invasion rates to be characterized among meningitis and fecal 
isolates. The adhesion portion of the assay could potentially be used for determining ligand-
receptor interactions and could be used to identify genes necessary for adhesion (in addition to 
OmpA). A library of mutated C. sakazakii BAA 894 could be constructed and then subjected to 
the adhesion assay. Mutants unable to adhere to EOMA cells could then be further studied for a 
genetic basis for differences seen between mutants and the wild type. Sequencing non-adherent 
mutants will help identify the sequences that are missing/altered. Once these regions are known, 
the intact gene(s) from the wild type could be isolated and cloned into a plasmid/reporter system 
and transformed back into the original mutant. Regaining the ability to adhere to cells will 
confirm the necessity for attachment. In addition, if the reporter system is fluorescently labeled, 
localized adhesion with EOMA cells could be identified and suspected receptors could be 
investigated. Receptors that are believed to be necessary for attachment could be blocked by 
antibodies tagged in an alternate fluorescent color. Maintained fluorescence associated with the 
mutated bacteria would indicate the correct receptor was not blocked while a lack of 
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fluorescence by the bacteria would confirm it is. Using the alternate fluorescent tag would 
confirm antibody attachment.  
 The supernatant assay could be used to study the possibility of toxin mediated damage in 
a number of ways. First, the supernatant could be heated before incubation to determine if heat 
labile toxins are present. An inability to cause the same damage would indicate the proteins were 
denatured while no change cytotoxicity would indicate heat stabile toxins or other factors present 
in the supernatant. If heat stabile toxins are present, the supernatant could be fractioned into 
separate components using high performance liquid chromatography. Once separated individual 
components could be incubated alone and in combination to determine which portion(s) are 
necessary for damage. In addition, the concentration necessary for damage could be determined 
using a serial dilution of the necessary component(s). If a portion of the supernatant is necessary 
to cause damage it could be identified multiple ways. Again a mutant library could be 
constructed to determine a possible genetic component. Alternately further purification of the 
component could be used to determine protein structure utilizing either crystallography or NMR.  
Researching the role of C. sakazakii motility in the contribution to biofilm formation 
could provide targets for prevention on manufacturing surfaces in the food industry. The ability 
to form biofilms on stainless steel could cause contamination in factories that produce either 
powdered infant formula or follow up formula. Preventing these biofilms from forming would 
help eliminate this route of contamination. The Pruess lab has investigated chemicals that inhibit 
or reduce biofilm formation in E. coli. These same chemicals could be screened with C. 
sakazakii to determine which may be suitable for use and whether they are effective with 
stainless steel.  
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 A collaboration with an engineering group could also be used to develop a novel 
microscopy system to study the time course of C. sakazakii penetration of both the astrocytes and 
EOMA cells. Combining the ideas of the TEER system and a simple flow cell, an advance type 
of flow cell could be created. This cell would allow for two cells lines to grow on opposites sides 
of a mesh surface that lies between two viewing surfaces. The device would allow for 
microscopy of both cell lines and would incorporate separate media lines for the divided sides of 
the device. The rate of media flow could be calibrated to mimic the rate of blood flow to the 
brain. 
 
 
 
 
 
 
Figure 17: Proposed Design for the Advanced Flow Cell. 
Experimentation could proceed as follows. Astrocytes and endothelial cells would be 
grown on the mesh surface similar to how a TEER insert is used. Confluency of both cell lines 
could be ensured by viewing either side of the device with a microscope. Once confluent, the 
media line to the side of the device containing EOMA cells would be inoculated with bacteria at 
rates known to cause meningitis in infants. If the bacteria are able to cross both cell lines, the 
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sterile media line for the astrocyte side of the cell would become contaminated. Images could be 
taken at any point of the experiment to determine how the cells are affected.  These images 
would show what the TEER system of cells look like at similar time points. It would also show 
whether confluency of either cell line is reduced.  
The TEER and advanced flow cell device could be provide even further insight into C. 
sakazakii interactions with the incorporation of other BBB cells such as pericytes and microglial 
cells which could be layered with the EOMA and astrocytes respectively. A number of advanced 
imaging techniques could be used to determine interactions at various locations and between all 
cell types. Utilizing these cell lines would more accurately reflect true blood brain barrier 
traversal and could be used to study bacterial mutants, cell receptor interactions and other 
pathogens as described previously.  
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